Search
Influenza A virus A/Minnesota/41/2019 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15701ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15702ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Nebraska/14/2019 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15707ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15710ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Hong Kong/2671/2019 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB15757ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Diffuse Large B-Cell Lymphoma (DLBCL)
go.drugbank.com/conditions/DBCOND0028221Synonyms: Malignant lymphoma, large B-cell, diffuse, no International Classification of Diseases for Oncology subtypeParamethasone
go.drugbank.com/drugs/DB01384Experimental(From Martindale, The Extra Pharmacopoeia, 30th ed, p737) … It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainIDM-2
go.drugbank.com/drugs/DB05293ExperimentalIDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Thalidomide
go.drugbank.com/drugs/DB01041ApprovedInvestigationalWithdrawnIt has been reintroduced and used for a number of inflammatory disorders and cancers. … A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects.
International brands: K-17Lumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1. … [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.